{
    "nctId": "NCT00088010",
    "briefTitle": "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer",
    "officialTitle": "Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.",
    "overallStatus": "COMPLETED",
    "conditions": "Osteoporosis, Postmenopausal",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 9369,
    "primaryOutcomeMeasure": "Effects of arzoxifene on bone fractures and bone mass",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 60-85 years of age\n* Female\n* At least two years since last menstrual cycle\n\nExclusion Criteria:\n\n* Abnormal or unexplained vaginal bleeding.\n* Bone disorders, other than osteoporosis or low bone mass\n* History of breast cancer, cancer of the uterus, or any cancer in the last five years (except skin cancer).\n* History of cerebral vascular accidents or venous thromboembolic events\n* Medications outlined",
    "sex": "FEMALE",
    "minimumAge": "60 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}